Metaiodobenzylguanidine (MIBG) is an analog of norepinephrine that accumulates in sympathetic nerve endings soon after intravenous administration. The degree of accumulation reflects the uptake, storage and release of transmitters by noradrenergic neurons. Myocardial imaging with 123I labeled MIBG ( 123I-MIBG) can be used to estimate the extent of local myocardial sympathetic nerve damage, which has been widely used in the diagnosis and treatment of various heart diseases. In recent years, numerous studies have been carried out on the application of 123I-MIBG in the diagnosis of degenerative diseases of the nervous system (such as Parkinson's disease and dementia of Lewy body), and have made some achievements. The purpose of this review is to summarize the current clinical application of 123I-MIBG myocardial imaging in the diagnosis of dementia with Lewy bodies, the problems in imaging technology and the possible research directions in the future, so as to provide valuable reference information for clinicians to reasonably and accurately apply this technology in the early diagnosis and discrimination of dementia.
间碘苄胍(MIBG)是去甲肾上腺素的类似物，静脉给药后很快就会在交感神经突触前囊泡内蓄积，蓄积程度反映去甲肾上腺素能神经元对递质的摄取、储存和释放能力。用 123碘（ 123I）标记的MIBG（ 123I-MIBG）进行心肌显像可以评估局部心肌交感神经的损伤程度，已广泛应用于多种心脏疾病的诊治。近年来，国内外学者对 123I-MIBG在神经系统变性的疾病（如帕金森病和路易体痴呆）诊断中的应用进行了大量研究，并取得了部分成果。本综述的目的是总结目前 123I-MIBG心肌成像在路易体痴呆的临床应用以及成像技术方面存在的问题和今后可能的研究方向，为临床医师在痴呆的早期诊断和鉴别中合理准确应用该技术提供有价值的参考信息。.
Keywords: 123I-metaiodobenzylguanidine; Dementia with Lewy bodies; Diagnostic biomarkers; Myocardial imaging.